Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

@article{Gill1995PhaseIC,
  title={Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.},
  author={Parkash S. Gill and Byron M. Espina and Franco Muggia and Suzanne Cabriales and Anil Tulpule and Joan A. Esplin and Howard A. Liebman and Eric A. Forssen and Mary Elizabeth Ross and Alexandra M. Levine},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1995},
  volume={13 4},
  pages={
          996-1003
        }
}
PURPOSE Since liposomal encapsulation of anticancer drugs may enhance antitumor activity while reducing toxicity in vitro, we evaluated liposomally encapsulated daunorubucin (DaunoXome; Vestar, Inc, San Dimas, CA) for safety, pharmacokinetics, and potential efficacy in patients with AIDS-related Kaposi's sarcoma (AIDS-KS). PATIENTS AND METHODS Forty patients with advanced AIDS-KS were accrued. Successive cohorts received DaunoXome at doses of 10, 20, 30, and 40 mg/m2 given once every 3 weeks… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 59 CITATIONS, ESTIMATED 64% COVERAGE

FILTER CITATIONS BY YEAR

1996
2019

CITATION STATISTICS

  • 7 Highly Influenced Citations